Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI

Reuters01-28

Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI

Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has amended its loan and security agreement with Hercules Capital, Inc. Under the revised terms, Savara will gain access to up to an additional $75 million in debt funding upon FDA approval of its investigational therapy MOLBREEVI for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). This amendment strengthens Savara’s balance sheet and liquidity as it prepares for a potential product launch. The agreement maintains the original maturity date and interest-only period, and does not include any warrants. Combined with a previously announced $75 million royalty funding agreement with RTW, Savara expects to have approximately $150 million in non-dilutive capital available to support MOLBREEVI’s launch activities.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260127749473) on January 27, 2026, and is solely responsible for the information contained therein.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2606731331?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-01-28 01:22","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2606731331","market":"nz","top_or_hot":-1,"title":"Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SVRA\">Savara Inc</a>., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has amended its loan and security agreement with <a href=\"https://laohu8.com/S/HCXZ\">Hercules Capital, Inc.</a> Under the revised terms, Savara will gain access to up to an additional $75 million in debt funding upon FDA approval of its investigational therapy MOLBREEVI for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). This amendment strengthens Savara’s balance sheet and liquidity as it prepares for a potential product launch. The agreement maintains the original maturity date and interest-only period, and does not include any warrants. Combined with a previously announced $75 million royalty funding agreement with RTW, Savara expects to have approximately $150 million in non-dilutive capital available to support MOLBREEVI’s launch activities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260127749473) on January 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nSavara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2026-01-28 01:22</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/SVRA\">Savara Inc</a>., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has amended its loan and security agreement with <a href=\"https://laohu8.com/S/HCXZ\">Hercules Capital, Inc.</a> Under the revised terms, Savara will gain access to up to an additional $75 million in debt funding upon FDA approval of its investigational therapy MOLBREEVI for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). This amendment strengthens Savara’s balance sheet and liquidity as it prepares for a potential product launch. The agreement maintains the original maturity date and interest-only period, and does not include any warrants. Combined with a previously announced $75 million royalty funding agreement with RTW, Savara expects to have approximately $150 million in non-dilutive capital available to support MOLBREEVI’s launch activities.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n<i>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260127749473) on January 27, 2026, and is solely responsible for the information contained therein.</span></i>\n</p>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4139","symbol_name":"生物科技","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260127:nNDL6z6r7Q:1","article_id":"2606731331","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2606731331","pubTimestamp":1769534567,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Savara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has amended its loan and security agreement with Hercules Capital, Inc. Under the revised terms, Savara will gain access to up to an additional $75 million in debt funding upon FDA approval of its investigational therapy MOLBREEVI for autoimmune pulmonary alveolar proteinosis . This amendment strengthens Savara’s balance sheet and liquidity as it prepares for a potential product launch. The agreement maintains the original maturity date and interest-only period, and does not include any warrants. Combined with a previously announced $75 million royalty funding agreement with RTW, Savara expects to have approximately $150 million in non-dilutive capital available to support MOLBREEVI’s launch activities.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"BK4139":"生物科技","SVRA":"Savara Inc","BK4135":"资产管理与托管银行","HTGC":"海格投资"},"translate_title":"Savara从Hercules Capital获得高达7500万美元的额外债务融资，等待FDA批准MOLBREEVI","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"SVRA":0.9,"HTGC":0.9},"content_text":"Savara Secures Up to $75 Million in Additional Debt Funding from Hercules Capital Pending FDA Approval of MOLBREEVI\n    \n\nSavara Inc., a clinical-stage biopharmaceutical company focused on rare respiratory diseases, has amended its loan and security agreement with Hercules Capital, Inc. Under the revised terms, Savara will gain access to up to an additional $75 million in debt funding upon FDA approval of its investigational therapy MOLBREEVI for autoimmune pulmonary alveolar proteinosis (autoimmune PAP). This amendment strengthens Savara’s balance sheet and liquidity as it prepares for a potential product launch. The agreement maintains the original maturity date and interest-only period, and does not include any warrants. Combined with a previously announced $75 million royalty funding agreement with RTW, Savara expects to have approximately $150 million in non-dilutive capital available to support MOLBREEVI’s launch activities.\n      \n\n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Savara Inc. published the original content used to generate this news brief via Business Wire (Ref. ID: 20260127749473) on January 27, 2026, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.36.2","shortVersion":"4.36.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2606731331","isCrawlerRequest":true}